Revagenix Doses First Participant In Phase 1 Trial Of Rev-56 For Non-Cystic Fibrosis Bronchiectasis

Revagenix, Inc., a biopharmaceutical company focused on developing targeted therapies for serious chronic diseases, has announced that the first participant has been dosed in the Phase 1 clinical trial of Rev-56, an investigational inhaled therapy for non-cystic fibrosis bronchiectasis (NCFB). The milestone marks the beginning of the clinical evaluation of what the company describes as a first-in-class treatment designed to target chronic *Pseudomonas aeruginosa* infections in patients with the disease.

Rev-56 has been developed to address one of the major drivers of disease progression in NCFB—chronic *Pseudomonas aeruginosa* infection—which is associated with more frequent disease exacerbations, increased hospitalisations, faster disease progression and higher mortality. Non-cystic fibrosis bronchiectasis is a serious and progressive respiratory condition that affects an estimated 350,000 to 500,000 adults in the United States, with millions more patients worldwide, highlighting the significant need for new treatment options.

The investigational therapy has been specifically engineered for inhaled delivery, allowing the medicine to be administered directly to the lungs. Revagenix says Rev-56 combines optimised physical properties with a novel mechanism of action and has the potential to be administered once daily, offering a convenient treatment approach that may improve patient adherence over the long term.

Commenting on the milestone, Ryan Cirz, Chief Executive Officer of Revagenix, said dosing the first participant represents an important achievement for the company and an encouraging step towards developing a targeted treatment for people living with non-cystic fibrosis bronchiectasis. He noted that Rev-56 was purpose-built for the disease, with a strong focus on creating a therapy that patients can use consistently over time.

Dr. Cirz added that the company designed Rev-56 by first considering the long-term needs of patients before developing the underlying science. He explained that the combination of inhaled delivery and a novel mechanism of action is intended to support consistent treatment use while maximising its potential clinical benefit. He also said the company looks forward to reporting topline results from Part A of the Phase 1 study later in 2026.

The initiation of the Phase 1 trial represents an important step in the clinical development of Rev-56 as Revagenix continues to evaluate its safety and potential as a targeted therapy for patients with non-cystic fibrosis bronchiectasis. If successful, the programme could provide a new treatment approach for a disease that currently has limited therapeutic options and continues to place a significant burden on patients and healthcare systems.